Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age

Journal of Clinical Endocrinology and Metabolism

Volumn 78, Issue 6, 1994, Pages 1360-1367

  Morales, Arlene J ^a,b   Nolan, John J ^a,b   Nelson, Jerald C ^a,b   Yen, Samuel S C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; ANDROSTENEDIONE; ESTRADIOL; ESTRONE; HIGH DENSITY LIPOPROTEIN; PLACEBO; PRASTERONE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN; TESTOSTERONE;

ADULT; AGED; AGING; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BODY FAT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; FEMALE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HORMONE DEFICIENCY; HORMONE DETERMINATION; HORMONE METABOLISM; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; INSULIN SENSITIVITY; LIBIDO; LIPID BLOOD LEVEL; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; WELLBEING;

ADULT; AGED; AGING; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BLOOD GLUCOSE; CARRIER PROTEINS; CHOLESTEROL; CIRCADIAN RHYTHM; DEHYDROEPIANDROSTERONE; DOUBLE-BLIND METHOD; FEMALE; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; LIBIDO; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PLACEBOS; SEX CHARACTERISTICS; TRIGLYCERIDES;

EID: 0028221213     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jcem.78.6.7515387     Document Type: Article

References (50)

1. Corpas E, Harman M, Blackman MR. 1993 Human growth hormone and human aging. Endocr Rev. 14:20-39.
2. Orentreich N, Brind JL, Rizer RL, Vogelman JH. 1984 Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab. 59:551-555.
3. Rudman D, Feller AG, Hoskote SN, et al. 1990 Effects of human growth hormone in men over 60 years old. N Engl J Med. 323:154.
4. McIntosh MK, Berdanier CD. 1991 Antiobesity effects of DHEA are mediated by futile substrate cycling in hepatocytes of BHE/cdb rats. JNutr. 121:2037-2043.
5. Gordon GB, Bush DE, Weisman HF. 1988 Reduction of atherosclerosis by administration of DHEA. J Clin Invest. 82:712-720.
6. Daynes RA, Araneo BA. 1992 Prevention and reversal of some age-associated changes in immunologic responses by supplemental dehydroepiandrosterone sulfate therapy. Aging Immun Infect Dis. 3:135-154.
7. Schwartz AG, Whitcomb JW, Nyce JW, et al. 1988 Dehydroepiandrosterone and structural analogs: a new class of cancer chemo-preventive agents. Adv Cancer Res. 51:391-424.
8. Cutler CB, Glenn M, Bush M, Hodgen GD, Graham CE, Loriaux DL. 1978 Adrenarche: a survey of rodents, domestic animals and primates. Endocrinology. 103:2112-2118.
9. van Weerden WM, Bierings HG, van Steenburgge GJ, de Jong FH, Schroder FH. 1992 Adrenal glands of mouse and rat do not synthesize androgens. Life Sci. 50:857-861.
10. Roth GS, Blackman MR, Ingram DK, Lane MA, Ball SS, Cutler RG. 1993 Age-related changes in androgen levels of rhesus monkeys subjected to diet restriction. Endocr J. 1:227-234.
11. Barrett-Connor E, Khaw K, Yen SSC. 1986 A prospective study of DS, mortality and cardiovascular disease. N Engl J Med. 315:1519-1524.
12. Helzlsouer KJ, Gordon GB, Alberg A, Bush TL, Comstock GW. 1992 Relationship of prediagnostic serum levels of DHEA and DS to the risk of developing premenopausal breast cancer. Cancer Res. 52:1-4.
13. Thoman ML, Weigle WO. 1989 The cellular and subcellular bases of immunosenescence. Adv Immunol. 46:221-261.
14. Contoreggi CS, Blackman MR, Andres R, et al. 1990 Plasma levels of estradiol, testosterone, and DS do not predict risk of coronary artery disease in men. J Androl. 11:460-470.
15. Barrett-Connor E, Kritz-SUverstein D, Edelsterin SL. 1993 A prospective study of DHEAS and bone mineral density in older men and women. Am J Epidemiol. 137:201-206.
16. Harrington DM, Gordon GB, Achuff SC, et al. 1990 Plasma DS in patients undergoing diagnostic coronary angiography. J Am Coll Cardiol. 16:862-870.
17. Nordin BEC, Robertson A, Seamark RF, et al. 1985 The relation between calcium absorption, serum DHEA and vertebral mineral density in postmenopausal women. J Clin Endocrinol Metab. 60:651-657.
18. Nestler JE, Barlascini CO, Clore JN, Blackard WG. 1988 Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab. 66:57-61.
19. Usiskin KS, Butterworth S, Clore JN, et al. 1990 Lack of effect of DHEA in obese men. Int J Obesity. 14:457-463.
20. Welle S, Jozefowicz R, Statt M. 1990 Failure of DHEA to influence energy and protein metabolism in humans. J Clin Endocrinol Metab. 71:1259-1264.
21. Mortola J, Yen SSC. 1990 The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab. 71:696-704.
22. Bird CE, Masters V, Clark AF. 1984 Dehydroepiandrosterone sulfate: kinetics of metabolism in normal young men and women. Clin Invest Med. 7:119-122.
23. Haning RV, Chabot M, Flood CA, Hackett R, Longcope C. 1989 Metabolic clearance rate (MCR) of dehydroepiandrosterone sulfate (DS), its metabolism to dehydroepiandrosterone, androstenedione, testosterone, and dihydrotestosterone, and the effect of increased plasma DS concentration on DS MCR in normal women. J Clin Endocrinol Metab. 69:1047-1052.
24. Gray A, Feldman HA, McKinlay JB, Longcope C. 1991 Age, disease, and changing sex hormone levels in middle-age men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 73:1016-1025.
25. Krause MV, Mahan LK. 1979 Food nutrition and diet therapy: a textbook on nutritional care. Philadelphia: Saunders: 194-196.
26. Khaled, MA, McCutcheon, MJ, Reddy S, Pearman PL, Hunter GR, Weinsier RL. 1988 Electrical impedance in assessing human body composition: the BIA method. Am J Clin Nutr. 47:789-792.
27. Segal KR, Loan MN, Fitzgerald FT, Hodon JA, Itallie TBV. 1988 Lean body mass estimation by bioelectrical analysis: a four site cross-validation study. Am J Clin Nutr. 47:7-14.
28. Renvall MJ, Spindler AA, Nichols JF, Ramsdell JW. 1993 Body composition of patients with Alzheimer’s disease. Am J Diet Assoc. 93:47-52.
29. Steil GM, Volund A, Kahn SE, Bergman RN. 1993 Reduced sample number for calculation of insulin sensitivity and glucose effectiveness from the minimal model. Diabetes. 42:250-256.
30. Bergman RN, Beard JC, Chen M. 1986 The minimal modeling method. Assessment of insulin sensitivity and B-cell function in vivo. Methods Diabetes Res. 2:15-34.
31. Freidenberg GR, Suter SL, Henry RR, Reichart D, Olefsky JM. 1991 In vivo stimulation of the insulin receptor kinase in human skeletal muscle. Correlation with insulin-stimulated glucose disposal during euglycemic clamp studies. J Clin Invest. 87:2222-2229.
32. Chiasson JL, Lilgenquist JE, Lacy WW, Jennings AS, Cherrington AD. 1977 Gluconeogenesis: methodological approaches in vivo. Fed Proc. 36:229-235.
33. Anderson DC, Hopper BR, Lasley BL, Yen SSC. 1976 A simple method for assay of eight steroids in small volumes of plasma. Steroids. 28:179-196.
34. Berga SL, Mortola JF, Girton L, et al. 1989 Neuroendocrine aberrations in women with functional hypothalamic amenorrhea. J Clin Endocrinol Metab. 68:301-308.
35. Daughaday WH, Mariz IK, Blethen SL. 1980 Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol extracted serum. J Clin Endocrinol Metab. 51:781-788.
36. Furlanetto RW, Underwood LE, Van Wyk JJ, D’Ercole AJ. 1977 Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay. J Clin Invest. 60:648-657.
37. Busby WH, Snyder DK, Clemmons DR. 1988 RIA of a 2600 dalton plasma insulin like growth factor binding protein: control by nutritional variables. J Clin Endocrinol Metab. 67:1225-1230.
38. Baxter RC, Martin JL. 1986 RIA of growth hormone dependent insulin-like growth factor binding protein in human plasma. J Clin Invest. 78:1504-1512.
39. Morgan CR, Lasarow A. 1963 Immunoassay of insulin: two antibody system. Diabetes, 12:115-126.
40. Segal P, Bachorik P, Rifkind B, Levy R. 1984 Lipids and dyslipo-proteinemia. In: Henry RB, ed. Clinical diagnosis and management by laboratory methods. Philadelphia: Saunders; 186-193.
41. Allain CA, Poon LS, Chan SCG, Richmond W, et al. 1974 Enzymatic determination of total serum cholesterol. Clin Chem. 20:470-475.
42. Veldhuis JD, Johnson ML. 1986 Cluster analysis: a simple, versatile, robust algorithm for endocrine pulse detection. Am J Physiol. 250:E486-E493.
43. Yeoh SI, Baxter RC. 1988 Metabolic regulation of the growth hormone independent insulin-like growth factor binding protein in human plasma. Acta Endocrinol (Copenh). 119:465-473.
44. O’Malley BW, Strott CA. 1991 Steroid hormones: metabolism and mechanism of action. In: Yen SSC, Jaffe RB, eds. Reproductive endocrinology. Philadelphia: Saunders; 162.
45. Holly JMP. 1991 The physiology role of IGFBP-1. Acta Endocrinol (Copenh). 124:55-62.
46. Clemmons DR. 1992. IGF binding proteins: regulation of cellular actions. Growth Regul. 2:80-87.
47. Snyder DK, Clemmons DR. 1990 Insulin-dependent regulation of insulin-like growth factor-binding protein-1. J Clin Endocrinol Metab. 71:1632-1636.
48. Tapanainen J, Ronnberg L, Martikainen H, Reinile M, Koistinen R, Seppala M. 1991 Short and long-term effects of growth hormone on circulating levels of insulin-like growth factor I, IGF binding protein-1 and insulin: a placebo-controlled study. J Clin Endocrinol Metab. 73:71-74.
49. Clemmons D. 1992 Editorial: role of insulin-like growth factor-1 in reversing catabolism. J Clin Endocrinol Metab. 75:1183-1185.
50. Robel P, Baulieu EE. 1994 Neurosteroids: biosynthesis and function. Trends Endocrinol Metab. 5:1-8.